Skip to main content

. 2003 Jul 15;89(2):422. doi: 10.1038/sj.bjc.6601020

SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer

J-L Boulay, G Mild, A Lowy, J Reuter, M Lagrange, L Terracciano, U Laffer, R Herrmann, C Rochlitz

PMCID: PMC2394240

Abstract

Correction to: British Journal of Cancer (2002) 87, 630–634. doi:10.1038/sj.bjc.6600511

Unfortunately due to a typesetting error, Figure 2 was reproduced uncorrectly.

Disease-free survival by 5-FU treatment (SMAD4 deleted).

The correct version is reprinted below:

The publisher would like to apologise for any inconvenience this may have caused.

ACTIONS

RESOURCES